235 related articles for article (PubMed ID: 34758713)
1. Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery.
Qin H; Zhang Y; Lou Y; Pan Z; Song F; Liu Y; Xu T; Zheng X; Hu X; Huang P
Curr Med Chem; 2022; 29(22):3922-3944. PubMed ID: 34758713
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.
Haines CN; Wardell SE; McDonnell DP
Essays Biochem; 2021 Dec; 65(6):985-1001. PubMed ID: 34328178
[TBL] [Abstract][Full Text] [Related]
3. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies.
Saatci O; Huynh-Dam KT; Sahin O
J Mol Med (Berl); 2021 Dec; 99(12):1691-1710. PubMed ID: 34623477
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Selective Estrogen Receptor Modulators in Breast Cancer Therapy: An Update.
Das A; Lavanya KJ; Nandini ; Kaur K; Jaitak V
Curr Med Chem; 2023; 30(29):3287-3314. PubMed ID: 36201273
[TBL] [Abstract][Full Text] [Related]
6. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance.
Lin X; Xiang H; Luo G
Eur J Med Chem; 2020 Nov; 206():112689. PubMed ID: 32829249
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted endocrine therapies for breast cancer.
Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer.
Li CL; Moi SH; Lin HS; Hou MF; Chen FM; Shih SL; Kan JY; Kao CN; Wu YC; Kao LC; Chen YH; Lee YC; Chiang CP
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142451
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.
Uray IP; Brown PH
Recent Results Cancer Res; 2011; 188():147-62. PubMed ID: 21253797
[TBL] [Abstract][Full Text] [Related]
10. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview.
Bhatia N; Hazra S; Thareja S
Eur J Med Chem; 2023 Aug; 256():115422. PubMed ID: 37163948
[TBL] [Abstract][Full Text] [Related]
11. Accelerating drug development in breast cancer: New frontiers for ER inhibition.
Ferraro E; Walsh EM; Tao JJ; Chandarlapaty S; Jhaveri K
Cancer Treat Rev; 2022 Sep; 109():102432. PubMed ID: 35839531
[TBL] [Abstract][Full Text] [Related]
12. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
Wang Y; Tang SC
Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
[TBL] [Abstract][Full Text] [Related]
13. Estrogen signaling: An emanating therapeutic target for breast cancer treatment.
Saha T; Makar S; Swetha R; Gutti G; Singh SK
Eur J Med Chem; 2019 Sep; 177():116-143. PubMed ID: 31129450
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
15. Selective degradation of the estrogen receptor in the treatment of cancers.
Wang Z; Ma Z; Shen Z
J Steroid Biochem Mol Biol; 2021 May; 209():105848. PubMed ID: 33610801
[TBL] [Abstract][Full Text] [Related]
16. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
17. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
18. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Lu Y; Liu W
J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
[TBL] [Abstract][Full Text] [Related]
19. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura S; Yue W; Berstein L
Endocr Relat Cancer; 2003 Jun; 10(2):111-30. PubMed ID: 12790774
[TBL] [Abstract][Full Text] [Related]
20. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
